Académique Documents
Professionnel Documents
Culture Documents
Review Article
nanomedjournal.com
Abstract
Gold nanoparticles (GNPs) are readily synthesised structures that absorb light strongly to generate thermal energy which induces
photothermal destruction of malignant tissue. This review examines the efficacy, potential challenges and toxicity from in vitro and in vivo
applications of GNPs in oesophageal, gastric and colon cancers. A systematic literature search of Medline, Embase, Web of Science and
Cochrane databases was performed using PRISMA guidelines. Two hundred and eighty-four papers were reviewed with sixteen studies
meeting the inclusion criteria. The application of GNPs in eleven in vivo rodent studies with GI adenocarcinoma demonstrated excellent
therapeutic outcomes but poor corroboration in terms of the cancer cells used, photothermal irradiation regimes, fluorophores and types of
nanoparticles. There is compelling evidence of the translational potential of GNPs to be complimentary to surgery and feasible in the
photothermal therapy of GI cancer but reproducibility and standardisation require development prior to GI cancer clinical trials.
From the Clinical Editor: Gold nanoparticles are one of the most potentially useful nanoparticles. This is especially true in cancer
therapeutics because of their photothermal properties. In this comprehensive article, the authors reviewed the application and efficacy of gold
nanoparticles in both the diagnosis and treatment of GI cancers. This review should provide a stimulus for researchers to further develop and
translate these nanoparticles into future clinical trials.
2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Key words: Gold nanoparticles; Gastrointestinal cancer; Photothermal therapy; Oesophageal; Gastric; Colon
http://dx.doi.org/10.1016/j.nano.2015.05.010
1549-9634/ 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Please cite this article as: Singh M, et al, Application of gold nanoparticles for gastrointestinal cancer theranostics: a systematic review. Nanomedicine:
NBM 2015;11:2083-2098, http://dx.doi.org/10.1016/j.nano.2015.05.010
2084
2085
2086
2087
Results
Initial searches using the MeSH terms above revealed 284
articles. There were nine conference abstracts (without accompanying full papers), which were excluded. A further 48 articles were
identified through free text searches, the related articles feature
and cross-referencing. Once duplicates were removed, finally 16
studies remained and were found to match the inclusion criteria,
thus these are discussed in this systematic review.
2088
Table 1
The included studies, with the type of study, shape, size and concentration of GNPs used in the study.
Study
Cells/animals
Shape
GNP concentration
Huang et al
Sazgarnia et al 144
Li et al 141
Cells + mice
Mice
Cells + rats
Rods
Spheres
Particles
46 18
6-8
30-90
Wu et al 143
Zhang et al 142
Puvanakrishnan et al 129
Goodrich et al 140
Brown et al 145
Black et al 146
Kirui et al 147
Cells
Cells
Mice
Mice
Cells
Cells
Mice
Particles
Particles
Shells
Rods
Particles
Rods
Hybrid particles
10
15
135
45 14
30-40
60 20
6-18
Gobin et al 23
Choi et al 148
Paciotti et al 149
Diagaradjane et al 139
Kirui et al 106
O'Neal et al 138
Mice
Mice
Mice
Mice
Cells
Mice
Shells
Particles
Particles
Shells
Rods
Shells
119
238
33
132-135
66 11
8-10
0.625-12.5 M
38.6 g/ml
OD 1 (cells) or 3 10 11 NP/ml
OD 50 (animals)
10 g/ml
20-100 M, OD 0.6
2.66 10 9 NP/ml, OD 1
4.5 ml/kg or OD 100 given IV to mice (2 10 13 GNR/ml)
?
?
PTT 200 L, 1 mg/ml
MRI 0.3 ml, 1 mg/ml
150 L (1.5 10 11/ml)
?
5-24 g
8 10 8/g body wt.
100 g/ml
100 ml of 2.4 10 11 NP/ml solution
137
2089
Table 2
Types of in vitro and in vivo GI cancer models and methods of inducing cancer in rodents.
Study
Cells
Animals
Inoculation method
Nude mice
BALB/c mice
SpragueDawley rats
Flank s/c
Flanks s/c
Esophago-duodenal anastomosis
HCT116, ATCC#CCL-247
human colon cancer cells
CT26.wt murine colon
carcinoma (ATCC)
Flank s/c
Brown et al 145
No
al 137
Huang et
Sazgarnia et al 144
Li et al 141
Black et al 146
Kirui et al 147
Gobin et al 23
No
Choi et al 148
No
No
No
Swiss nu/nu mice
Balb/c mice
No
Balb/c nude mice
BALB/c mice
BALB/c mice
s/c
A/J mice
Azoxymethane (AOM)-induced
orthotopic colon cancer models.
MC-38 colon carcinoma cells
s/c
HCT 116 human colorectal cancer cells 2 10 6 cells s/c into
right thigh.
C57/BL6 mice
Nude Swiss mice
Kirui et al 106
No
O'Neal et al 138
BALB/c mice
Paciotti et al 149
No
Diagaradjane et al 139 No
SW 1222 (106 cells/ml)
human colorectal cancer cells
No
Flank s/c
BALB/c AnNHsd
CT26.WT murine colon
SpragueDawley mice carcinoma tumour cells (ATCC)
2090
Table 3
Irradiation regimes used in each study model.
Study
Cells/animals
Irradiation used
Duration of radiation
CW laser 808 nm
3 mins
Sazgarnia et al 144
Mice
Li et al 141
Zhang et al 142
Cells
30 mW laser power
4 W/cm 2 laser fluence
US: 2 W/cm 2, with frequency 1.1 MHz
Light: 35 J/cm 2
Goodrich et al 140
Black et al 146
Mice
Cells
CW laser 808 nm
Ti:Sapphire at 800 nm
Kirui et al 147
Mice
CW laser 808 nm
Gobin et al 23
Diagaradjane et al 139
Mice
Mice
Kirui et al 106
O'Neal et al 138
Cells
Mice
CW laser at 808 nm
808 nm CW laser + a single
10 Gy dose of radiation therapy
using 125 kV X-ray operated at 20 mA
CW laser 808 nm
CW laser 808 nm
Huang et
al 137
3 W/cm 2
1 Gy/min
US 3 mins
IPL 9 pulses of 5 ms
pulse duration
Cells & rats, 1 min at
3 W/cm 2, or, 30 sec, 1 W/cm 2
Cells exposed to 2, 6 & 10 Gy
with corresponding irradiation
times of 2, 6 & 10 min
180 seconds
No time duration specified just
states 4 passes"
30 mins & 7 rounds therapy
over 14 days
3 mins
20 minutes
10 mins
3 mins
2091
137
Summary of evidence
Gold nanoparticle type and concentration
With the exception of one study that used GNPs of 238 nm, 148
all other studies have used GNPs (of different shapes) below
2092
Charge of nanoparticles
Most studies 12/16 (75%) did not involve GNP functionalisation with a targeting agent, solely utilising the EPR effect for
tumour localisation. Goodrich et al state that their previous
experience using the concept of EPR for assessing the
biodistribution of infused GNP to tumour found that less than
10% of the total injected dose actually reaches the tumour. 140
137
Folic acid was used for targeting gastric cancer cells whilst
the A33 antigen 106,147 and hyaluronic acid receptor 148 were used
in targeting CRC. It remains to be proven if there is a definite
combination of active and passive targeting that would provide
ideal cancer targeting, but this would need to be balanced against
the risks of provoking heat-induced bleeding or perforation if
applied on more advanced (T3 or T4) cancers.
Cancer models used
There have been eleven in vivo rodent experiments, mostly
with superficial tumours inoculated through subcutaneous
injection of cancer cell lines in rodents. 23,129,137-141,144,147-149
Other ways of inducing cancer include intraperitoneal injection
of azoxymethane (AOM) in A/J mice. AOM treatment is used to
induce colonic tumours as it mimics the adenoma-to-carcinoma
sequence of CRCs in humans. 148 Oesophageal cancer was
induced orthotopically by mucosa-to-mucosa anastomosis
Irradiation regimes
2093
Discussion
The information presented here is encouraging in demonstrating
that GNPs do have the potential to be excellent tumour targeting
agents due to their ability to extravasate from leaky endothelial walls
surrounding a GI cancer, and remain in-situ sufficiently long to
absorb NIR light and generate heat that is capable of destroying
cancer cells. Active targeting to tumours can also be accomplished
by conjugation with moieties that are over-expressed on cancer cells,
namely antibodies, folic acid and peptides.
Further chemical refinement of NPs is being developed, such
that the cytotoxicity of these particles is becoming much less
pronounced. Despite the GI studies that have been conducted, we
appear to be far away from conducting a clinical trial, unless
there is a concerted effort to minimise variations in synthesised
GNPs and the concentrations used in in vivo experiments. Thus
further GI theranostics research needs to focus on the challenges
remaining in representing nanotechnology as a viable and safe
adjunct to surgery. This focus should not solely be on proving
tumour regression, but also on examining acute and long term in
vivo toxicity, with sufficiently powered studies which assess safe
and optimal GNP doses and laser fluence.
This systematic review has identified a cohort of in vivo
studies using GI cancer cells that have been implanted and grown
subcutaneously in rodents, however there have only been 2
studies 141,148 where the tumour has actually been established in
an orthotopic (in-situ) model. Thermally ablating a superficial
surface tumour with an external laser beam would present a
lower risk profile than attempting the same endeavour
intracorporeally with endoscopically-delivered NIR irradiation,
where there would be additional factors and challenges to
consider, but is vital to adequately assess and quantify that risk.
In order to accomplish this, more orthotopic models of cancer
should be studied with different modes of administering GNPs
(intravenous, intratumoural or spraying) and laser treatment, to
address the factors involved in bringing this technology to the
forefront of clinical application. The depth of NIR penetration
that can be efficaciously applied to a GI tumour region also needs
to be quantified, so as to be certain about its applicability when
given through the surface of the skin or organ. It is interesting in
itself that none of the studies in this review provided any
information about the absorption or attenuation co-efficients of
tissues with or without GNPs, but this is a factor that limits the
depth of effective NIR delivery and thus heating.
2094
References
1. Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk
of developing cancer in Great Britain: comparison of risk for those born
from 1930 to 1960. Br J Cancer 2015;112(5):943-7.
2. Mukherjee S. The emperor of all maladies. A biography of cancer.
Harper Collins Publisher978-0-00-725092-9; 2011.
3. UK Oesophageal Cancer Incidence Statistics, Cancer Research UK.
http://wwwcancerresearchukorg/cancer-info/cancerstats/types/
oesophagus/incidence/uk-oesophageal-cancer-incidence-statistics.
2095
25. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE,
et al. Nanoshell-mediated near-infrared thermal therapy of tumors
under magnetic resonance guidance. Proc Natl Acad Sci U S A
2003;100(23):13549-54.
26. Loo C, Lin A, Hirsch L, Lee M-H, Barton J, Halas N, et al. Nanoshellenabled photonics-based imaging and therapy of cancer. Technol
Cancer Res Treat 2004;3(1):33-40.
27. Ji X, Shao R, Elliott AM, Stafford RJ, Esparza-Coss E, Bankson JA, et al.
Bifunctional gold nanoshells with a superparamagnetic iron oxide-silica
core suitable for both MR imaging and photothermal therapy. J Phys
Chem C Nanomater Interfaces 2007;111(17):6245-51.
28. Li M-L, Wang JC, Schwartz JA, Gill-Sharp KL, Stoica G, Wang LV.
In-vivo photoacoustic microscopy of nanoshell extravasation from
solid tumor vasculature. J Biomed Opt 2009;14(1):010507.
29. Ding H, Yang D, Zhao C, Song Z, Liu P, Wang Y, et al. Protein-gold
hybrid nanocubes for cell imaging and drug delivery. ACS Appl Mater
Interfaces 2015;7(8):4713-9.
30. Jia X, Cai X, Chen Y, Wang S, Xu H, Zhang K, et al. Perfluoropentaneencapsulated hollow mesoporous Prussian blue nanocubes for activated
ultrasound imaging and photothermal therapy of cancer. ACS Appl
Mater Interfaces 2015;7(8):4579-88.
31. Kolosnjaj-Tabi J, Di Corato R, Lartigue L, Marangon I, Guardia P,
Silva A, et al. Heat-generating iron oxide nanocubes: subtle
destructurators" of the tumoral microenvironment. ACS Nano
2014;8(5):4268-83.
32. Bae KH, Park M, Do MJ, Lee N, Ryu JH, Kim GW, et al. Chitosan
oligosaccharide-stabilized ferrimagnetic iron oxide nanocubes for magnetically modulated cancer hyperthermia. ACS Nano 2012;6(6):5266-73.
33. Lartigue L, Alloyeau D, Kolosnjaj-Tabi J, Javed Y, Guardia P,
Riedinger A, et al. Biodegradation of iron oxide nanocubes: highresolution in situ monitoring. ACS Nano 2013;7(5):3939-52.
34. Wu X, Ming T, Wang X, Wang P, Wang J, Chen J. Highphotoluminescence-yield gold nanocubes: for cell imaging and
photothermal therapy. ACS Nano 2010;4(1):113-20.
35. Kalluru P, Vankayala R, Chiang C-S, Hwang KC. Photosensitization of
singlet oxygen and in vivo photodynamic therapeutic effects mediated
by PEGylated W(18)O(49) nanowires. Angew Chem Int Ed Engl
2013;52(47):12332-6.
36. Chen Z, Wang Q, Wang H, Zhang L, Song G, Song L, et al. Ultrathin
PEGylated W18O49 nanowires as a new 980 nm-laser-driven photothermal agent for efficient ablation of cancer cells in vivo. Adv Mater
2013;25(14):2095-100.
37. Su Y, Wei X, Peng F, Zhong Y, Lu Y, Su S, et al. Gold nanoparticlesdecorated silicon nanowires as highly efficient near-infrared hyperthermia
agents for cancer cells destruction. Nano Lett 2012;12(4):1845-50.
38. Park G-S, Kwon H, Kwak DW, Park SY, Kim M, Lee J-H, et al. Full
surface embedding of gold clusters on silicon nanowires for efficient
capture and photothermal therapy of circulating tumor cells. Nano Lett
2012;12(3):1638-42.
39. Wu Z, Wu Y, He W, Lin X, Sun J, He Q. Self-propelled polymer-based
multilayer nanorockets for transportation and drug release. Angew
Chem Int Ed Engl 2013;52(27):7000-3.
40. Chen H, Zhang X, Dai S, Ma Y, Cui S, Achilefu S, et al. Multifunctional
gold nanostar conjugates for tumor imaging and combined photothermal
and chemo-therapy. Theranostics 2013;3(9):633-49.
41. Dam DHM, Culver KSB, Sisco PN, Odom TW. Shining light on
nuclear-targeted therapy using gold nanostar constructs. Ther Deliv
2012;3(11):1263-7.
42. Li W, Sun X, Wang Y, Niu G, Chen X, Qian Z, et al. In vivo
quantitative photoacoustic microscopy of gold nanostar kinetics in
mouse organs. Biomed Opt Express 2014;5(8):2679-85.
43. Kereselidze ZRV, Peralta XG, Santamaria F. Gold nanostar synthesis
with a silver seed mediated growth method. J Vis Exp 2012;59:3570.
44. Ma W, Sun M, Xu L, Wang L, Kuang H, Xu C. A SERS active gold
nanostar dimer for mercury ion detection. Chem Commun (Camb)
2013;49(44):4989-91.
2096
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
2097
114. Chen Y-S, Hung Y-C, Liau I, Huang GS. Assessment of the in vivo
toxicity of gold nanoparticles. Nanoscale Res Lett 2009;4(8):858-64.
115. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal
uptake of biodegradable microparticles: effect of particle size. Pharm
Res 1996;13(12):1838-45.
116. Hede S, Huilgol N. "Nano": the new nemesis of cancer. J Cancer Res
Ther 2006;2(4):186-95.
117. Moghimi S, Hunter A, Murray J. Nanomedicine: current status and
future prospects. FASEB J 2005;19(3):311-30.
118. Thornton G. Materials science. Watching nanoparticles grow. Science
2003;300(5624):1378-9.
119. Gratton SEA, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME,
et al. The effect of particle design on cellular internalization pathways.
Proc Natl Acad Sci U S A 2008;105(33):11613-8.
120. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge
of nanoparticles determines their endocytic and transcytotic pathway in
polarized MDCK cells. Biomacromolecules 2008;9(2):435-43.
121. Sahay G, Kim JO, Kabanov AV, Bronich TK. The exploitation of
differential endocytic pathways in normal and tumor cells in the
selective targeting of nanoparticulate chemotherapeutic agents.
Biomaterials 2010;31(5):923-33.
122. Lund T, Callaghan MF, Williams P, Turmaine M, Bachmann C,
Rademacher T, et al. The influence of ligand organization on the rate of
uptake of gold nanoparticles by colorectal cancer cells. Biomaterials
2011;32(36):9776-84.
123. Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R,
Robertson JD, et al. Effect of nanoparticle surface charge at the plasma
membrane and beyond. Nano Lett 2010;10(7):2543-8.
124. Zahr AS, Davis CA, Pishko MV. Macrophage uptake of core-shell
nanoparticles surface modified with poly(ethylene glycol). Langmuir
2006;22(19):8178-85.
125. Durr NJ, Larson T, Smith DK, Korgel BA, Sokolov K, Ben-Yakar A.
Two-photon luminescence imaging of cancer cells using molecularly
targeted gold nanorods. Nano Lett 2007;7(4):941-5.
126. Kim K, Huang S-W, Ashkenazi S, ODonnell M, Agarwal A, Kotov N,
et al. Photoacoustic imaging of early inflammatory response using gold
nanorods. Appl Phys Lett 2007;90:223901.
127. Park J, Estrada A, Schwartz JA, Diagaradjane P, Krishnan S, Dunn AK,
et al. Intra-organ biodistribution of gold nanoparticles using
intrinsic two-photon induced photoluminescence. Lasers Surg Med
2010;42(7):630-9.
128. Copland JA, Eghtedari M, Popov VL, Kotov N, Mamedova N,
Motamedi M, et al. Bioconjugated gold nanoparticles as a molecular
based contrast agent: implications for imaging of deep tumors using
optoacoustic tomography. Mol Imaging Biol 2004;6(5):341-9.
129. Puvanakrishnan P, Park J, Diagaradjane P, Schwartz JA, Coleman CL,
Gill-Sharp KL, et al. Near-infrared narrow-band imaging of gold/silica
nanoshells in tumors. J Biomed Opt 2009;14(2):024044.
130. Oldenburg AL, Hansen MN, Ralston TS, Wei A, Boppart SA. Imaging
gold nanorods in excised human breast carcinoma by spectroscopic
optical coherence tomography. J Mater Chem 2009;19:6407, http://
dx.doi.org/10.1039/b823389f.
131. Cai Q-Y, Kim SH, Choi KS, Kim SY, Byun SJ, Kim KW, et al.
Colloidal gold nanoparticles as a blood-pool contrast agent for X-ray
computed tomography in mice. Invest Radiol 2007;42(12):797-806.
132. Kim D, Park S, Lee JH, Jeong YY, Jon S. Antibiofouling polymercoated gold nanoparticles as a contrast agent for in vivo X-ray
computed tomography imaging. J Am Chem Soc 2007;129(24):7661-5.
133. Xie H, Goins B, Bao A, Wang ZJ, Phillips WT. Effect of intratumoral
administration on biodistribution of 64Cu-labeled nanoshells. Int J
Nanomedicine 2012;7:2227-38.
134. Xie H, Wang ZJ, Bao A, Goins B, Phillips WT. In vivo PET imaging
and biodistribution of radiolabeled gold nanoshells in rats with tumor
xenografts. Int J Pharm 2010;395(1-2):324-30.
135. Wang YLY, Luehmann H, Xia X, Brown P, Jarreau C, Welch M, et al.
Evaluating the pharmacokinetics and in vivo cancer targeting capability
2098
136.
137.
138.
139.
140.
141.
142.
143.